Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Pharmobedient

Drug and asset intelligence for Pharmobedient with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
5
Catalysts
5
Stage
Development stage unavailable

Mechanism of action

Chemotherapy

Recent signals(5)

RegulatoryJune 28, 2026

FDA Approval Update for Acetaminophen and Codeine Phosphate by Pharmobedient

The FDA has issued an approval letter for ANDA087006 concerning Acetaminophen and Codeine Phosphate.

RegulatoryJune 26, 2026

FDA Approval Status Update for Acetaminophen, Caffeine, and Dihydrocodeine Bitartrate

The FDA has provided an approval status update for ANDA204209, a combination product containing acetaminophen, caffeine, and dihydrocodeine bitartrate.

RegulatoryJune 24, 2026

FDA Approval Status Update for Oxycodone Hydrochloride by Pharmobedient

The FDA has provided an approval status update for ANDA206456, a supplemental application for Oxycodone Hydrochloride submitted by Pharmobedient.

RegulatoryJune 21, 2026

FDA Accepts ANDA for Doxylamine Succinate and Pyridoxine Hydrochloride

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Doxylamine Succinate and Pyridoxine Hydrochloride submitted by Pharmobedient.

RegulatoryJune 21, 2026

FDA Grants AP Status for Azacitidine ANDA204949 by Pharmobedient

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Azacitidine submitted by Pharmobedient.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(5)

Topline Data

— Pharmobedient

June 28, 2026 · N/A

Topline Data

— PHARMOBEDIENT

June 26, 2026 · N/A

Topline Data

— Pharmobedient

June 24, 2026 · N/A

Topline Data

— Pharmobedient

June 21, 2026 · N/A

Topline Data

— Pharmobedient

June 21, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Chemotherapy →
Combination Analgesics →
Nausea and Vomiting in Pregnancy →
Oncology →
Oncology · Chemotherapy →
Opioid →
Pain Management →
Pain Management · Combination Analgesics →
Pain Management · Opioid →
Women's Health →
Women's Health · Nausea and Vomiting in Pregnancy →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.